{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T09:18:34Z","timestamp":1694769514705},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Hypertrophic cardiomyopathy (HCM) is mainly caused by mutations in genes encoding sarcomeric proteins. One of the most commonly mutated HCM genes is the <jats:italic toggle=\"yes\">MYBPC3<\/jats:italic> gene. Mutations in this gene lead mainly to truncation of the protein, which gives rise to a relatively severe phenotype. Analyses of gene mutations associated with HCM are valuable for molecular diagnosis, genetic counseling, and management of familial HCM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 12-year-old boy presented with palpitations and dyspnea after exercise for 1 year. Echocardiography showed myocardial asymmetric hypertrophy of the ventricular septum, the anterior wall, and the lateral wall of the left ventricle. The thickness of the interventricular septum was estimated to be 33\u200amm. ECG showed left ventricular high voltage and ST-T changes. He had been diagnosed with HCM 3 months previously.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Due to his clinical presentation, he was determined to have HCM via a molecular analysis, revealing compound heterozygotes (p.R597W and p.Q1012Sfs\u22178) in the <jats:italic toggle=\"yes\">MYBPC3<\/jats:italic> gene.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was prescribed metoprolol to slow the heart rate and increase diastolic filling time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The boy was treated with metoprolol 6.75\u200amg b.i.d. Approximately 3 months later, review of the echocardiography showed that the peak velocity across the LVOT dropped to 2.3\u200am\/seconds and that the pressure gradient dropped to 21\u200amm Hg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>A custom next-generation sequencing (NGS) technology for the HCM panel allowed us to identify compound heterozygous mutations in the <jats:italic toggle=\"yes\">MYBPC3<\/jats:italic> gene, confirming NGS as a molecular diagnostic tool.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014676","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T11:50:14Z","timestamp":1553169014000},"page":"e14676","source":"Crossref","is-referenced-by-count":2,"title":["Next-generation sequencing (NGS) as a molecular diagnostic tool for hypertrophic cardiomyopathy in a Chinese boy due to novel compound heterozygous mutations in the MYBPC3 gene"],"prefix":"10.1097","volume":"98","author":[{"given":"Xu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Echocardiography, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian Province."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Macro & Micro-Test Bio-Tech Co., Ltd., No. 28 Yuhua Road, Airport High-Tech Park, Shunyi District, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Echocardiography, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian Province."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Echocardiography, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian Province."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maolong","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Echocardiography, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, Fujian Province."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/hrt.2007.127241","article-title":"Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish","volume":"94","author":"Zahka","year":"2008","journal-title":"Heart"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ejhg.2010.243","article-title":"Clinical utility gene card for: hypertrophic cardiomyopathy (type 1-14)","volume":"19","author":"Pinto","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCRESAHA.110.223834","article-title":"Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history","volume":"108","author":"Seidman","year":"2011","journal-title":"Circ Res"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.hlc.2011.07.017","article-title":"Guidelines for the diagnosis and management of hypertrophic cardiomyopathy","volume":"20","author":"Semsarian","year":"2011","journal-title":"Heart Lung Circ"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa021715","article-title":"The incidence of pediatric cardiomyopathy in two regions of the United States","volume":"348","author":"Lipschultz","year":"2003","journal-title":"New Engl J Med"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa021737","article-title":"The epidemiology of childhood cardiomyopathy in Australia","volume":"348","author":"Nugent","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/01.CIR.65.1.7","article-title":"Hypertrophic cardiomyopathy in infants: clinical features and natural history","volume":"65","author":"Maron","year":"1982","journal-title":"Circulation"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00001573-199905000-00010","article-title":"Genetics of neonatal cardiomyopathy","volume":"14","author":"Towbin","year":"1999","journal-title":"Curr Opin Cardiol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ejhg.2014.211","article-title":"Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects","volume":"23","author":"Wessels","year":"2015","journal-title":"EJHG"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yjmcc.2016.03.003","article-title":"Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue","volume":"97","author":"Wijnker","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCGENETICS.113.000448","article-title":"Sarcomere mutationspecific expression patterns in human hypertrophic cardiomyopathy","volume":"7","author":"Helms","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/jcp.25639","article-title":"The role of cardiac myosin binding protein C3 in hypertrophic cardiomyopathy-progress and novel therapeutic opportunities","volume":"232","author":"Mohamed","year":"2017","journal-title":"J Cell Physiol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","article-title":"A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation","volume":"62","author":"Geisterfer-Lowrance","year":"1990","journal-title":"Cell"},{"issue":"(Pt 1)","key":"R15-20230914","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1242\/jcs.109.1.101","article-title":"The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle","volume":"109","author":"Gilbert","year":"1996","journal-title":"J Cell Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903220-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:19:02Z","timestamp":1694719142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903220-00005"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014676","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}